In November 2025, the National Medical Products Administration (NMPA), along with the Guangdong and Jiangxi Provincial Medical Products Administrations, successively issued notices on cosmetic sampling inspections and regulatory supervision. A total of 71 batches of products were found to be non-compliant.
This article provides a consolidated overview of the relevant regulatory notices, supplemented by recent developments in regulatory enforcement activities-such as unannounced inspections and sampling inspections-conducted by the National Medical Products Administration (NMPA) and selected provincial and municipal authorities. The aim is to assist enterprises in staying informed of evolving regulatory trends and to reinforce awareness of quality management and compliance requirements.
Cosmetic Supervision and Sampling Inspection Data
Announcement of the National Medical Products Administration on 48 Batches of Non-compliant Cosmetics (2025 No. 41)
On November 14, 2025, the National Medical Products Administration (NMPA) announced that, as part of the 2025 national cosmetic sampling inspection program, 48 batches of cosmetics were found to be non-compliant following testing conducted by the Guangxi Zhuang Autonomous Region Institute for Drug Control and other institutions. The non-compliant products include aloe gels, facial masks, shampoos, and others. The non-compliance issues involve total bacterial count, acrylamide content, and ingredient consistency, among other items.
https://www.nmpa.gov.cn/xxgk/ggtg/hzhpggtg/hzhpchjgg/hzhpcjgjj/20251114180134122.html
Announcement of the Guangdong Provincial Medical Products Administration on Cosmetic Sampling Inspection Information (2025 Issue No. 3)
On November 7, 2025, the Guangdong Provincial Medical Products Administration issued a notice stating that, in accordance with the Guangdong Provincial Cosmetic Sampling Inspection Plan, it organized sampling inspections of cosmetics across the province’s production and distribution sectors. A total of 23 batches of cosmetics were found to be non-compliant. The non-compliant products include body wash, hair dye cream, and sunscreen lotion. The non-compliance issues include the detection of hair dye ingredients – such as m-aminophenol – that were not indicated on the product labels as required by the technical specifications registered or filed, as well as excessive total bacterial count.
https://mpa.gd.gov.cn/zwgk/jgsz/jcj/cjxx/hzp/content/post_4795246.html
Cosmetic Safety “You Choose, We Inspect” Sampling Inspection Announcement (2025 Batch 2)
On November 24, 2025, the Jiangxi Provincial Medical Products Administration issued an announcement regarding the second batch of sampling inspections under its “You Choose, We Inspect” initiative for cosmetic safety. In accordance with the Jiangxi Provincial Medical Products Administration’s 2025 work plan for this program, drug regulatory authorities across the province have actively organized themed activities in various formats to engage the public in cosmetic safety oversight.
Based on consumer input collected through the program, the second batch of inspections in 2025 covered 21 cosmetic product samples across six major categories: general skincare, sun protection, shampoo and hair care, cleansing and bathing, acne treatment claims, nail polish (including toenail polish), and toothpaste. All sampled products were found to be compliant with applicable regulations.
https://mpa.jiangxi.gov.cn/jxsypjdglj/col/col45622/content/content_1992812989786361856.html
Cosmetic Supervision and Sampling Inspection Data
Announcement on Provincial-Level Cosmetic Manufacturing Supervision and Inspection Information by Anhui Provincial Medical Products Administration (2025 Issue No. 2)
On November 17, 2025, the Anhui Provincial Medical Products Administration released its second announcement of 2025 regarding provincial-level supervision and inspection of cosmetic manufacturing.
According to the announcement, one cosmetic manufacturer was found to be non-compliant with relevant regulations. The enterprise was ordered to rectify the issues within a prescribed time frame and was subjected to regulatory measures such as official interviews and suspension of production and business operations. A case has also been filed for further investigation. In addition, three other enterprises received inspection conclusions of “basically compliant” and were also ordered to complete corrective actions within a specified period in accordance with the law.
https://mpa.ah.gov.cn/public/4140867/123187341.html
Announcement on the Results of Cosmetic Supervision and Inspection by Guizhou Provincial Medical Products Administration (2025 Issue No. 5)
On November 18, 2025, the Guizhou Provincial Medical Products Administration released its fifth announcement of 2025 regarding the results of cosmetic supervision and inspection. According to the announcement, from October 16 to 17, 2025, the Inspection Center of the Guizhou Provincial Medical Products Administration organized inspectors to conduct a supervisory inspection of Guizhou Xinrongcheng Industrial Co., Ltd. The inspection revealed serious deficiencies in the company’s cosmetic production quality management system. As a result, regulatory authorities have imposed risk control measures on the company, including the suspension of its cosmetic production and business operations.
https://yjj.guizhou.gov.cn/gsgg/yplttg/202511/t20251118_88952673.html
About CIRS
The CIRS cosmetic team is dedicated to ensuring that cosmetic products meet stringent global regulatory standards. It can provide one-stop services covering the whole life-cycle of a personal care product, which includes cosmetic ingredient development, physical/chemical tests, toxicological tests (in vivo & in vitro), efficacy studies (in vivo & in vitro), ingredient registration, and product registration.
Cosmetic services in China:
- China Cosmetic Registration and Filing;
- China New Cosmetic Ingredient Registration and Filing;
- China Cosmetic Ingredient Quality and Safety Information Code Application (NMPA Code);
- China Cosmetics Efficacy Evaluation;
- In-vitro Safety and Efficacy Evaluation;
- China Cosmetic Safety Assessment Report;
- China Toothpaste Filing;
- China Disinfectant Notification;
- China Cosmetic Formula/Label/Claim Review; and
- Customs Clearance
If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.
